Bcl11b as a biomarker for breast cancer patients to improve chemotherapy efficacy utilizing tnf-alpha treatment

Abstract

Disclosed herein is the identification of the biomarker, BCL11B, in breast cancer, which is associated with an increased risk of relapse after chemotherapy. In an embodiment, a method of identifying a subset of breast cancer patients at high risk of developing chemotherapy resistance is provided, the method comprising determining the prevalence of BCL11B expression in a population of breast cancer cells, where higher levels of BCL11B expressing cells identify an individual with a higher risk of resistance when receiving chemotherapy. Individuals may be treated accordingly to decrease the risk of relapse.

Dependencies are inferred from the claim text.